Phase I study of veliparib in combination with gemcitabine

Ronald G. Stoller,John C. Schmitz,Fei Ding,Shannon Puhalla,Chandra P. Belani,Leonard Joseph Appleman,Yan Lin,Yixing Jiang,Salah Almokadem,D. Petro,Julianne L. Holleran,Brian F. Kiesel,R. Ken Czambel,Benedito A. Carneiro,Emmanuel Kontopodis,Pamela A. Hershberger,Madani Rachid,Alice Chen,Edward Chu,Jan H. Beumer

Phase I study of veliparib in combination with gemcitabine

2017

Background Veliparib (ABT-888) is an oral PARP inhibitor expected to increase gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose-limiting toxicities (DLT), antitumor activity, pharmacokinetics (PK), and pharmacodynamics (PD) of veliparib combined with gemcitabine.

Keywords:

Pharmacology
Veliparib
PARP inhibitor
Pharmacodynamics
Gemcitabine
Medicine
Pharmacokinetics
Deoxycytidine
phase i study
antitumor activity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations